Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
ISO 81060-2:2019 / CSA ISO 81060-2:19: Clinical Validation of Non-Invasive Automated Sphygmomanometers
Technical Scope, Validation Protocol Requirements, and Global Compliance for Blood Pressure Monitors
The accuracy of automated non-invasive blood pressure (NIBP) monitors is a cornerstone of effective cardiovascular diagnosis and patient management. Serving as the definitive global benchmark for clinical performance assessment, ISO 81060-2:2019 (published in Canada as CSA ISO 81060-2:19) outlines the rigorous protocol that manufacturers must follow to validate their devices. This article details the essential technical facets of this standard, focusing on scope, strict validation criteria, and implementation pathways.
Scope and Purpose of the Standard
ISO 81060-2:2019 specifies the requirements and methods for the clinical investigation of intermittent, automated, non-invasive blood pressure measurement devices. This includes devices used on the upper arm, wrist, and thigh. The standard provides an unambiguous framework for determining the systematic bias (mean error) and precision (standard deviation) of a test device when compared against a clinically accepted reference standard. It replaces the grading system of the 2013 edition with a definitive binary pass/fail system, significantly tightening the pathway to market access.
Clinical Relevance: This standard ensures that blood pressure readings from automated devices are accurate enough for their intended clinical purpose, whether for diagnosis, monitoring, or treatment decisions in general practice, hospitals, or home settings.
Core Technical Requirements and Validation Protocol
The standard is highly prescriptive in its methodology to minimize bias and ensure statistical power across diverse patient populations. It mandates a sequential same-arm comparison between the test device and the reference standard.
Subject Demographics and Blood Pressure Distribution
A critical element of the protocol is the required distribution of blood pressure among the subjects. This ensures the device is tested across the full physiological range of intended use. The table below summarizes the required distribution for Systolic Blood Pressure (SBP).
| SBP Baseline Range (mmHg) | Required Proportion of Subjects |
|---|---|
| < 100 | 5% – 15% |
| 100 – 129 | 20% – 40% |
| 130 – 159 | 25% – 50% |
| 160 – 179 | 10% – 30% |
| ≥ 180 | 5% – 15% |
Validation Criteria (Criterion 1 and 2)
The 2019 edition introduces a rigorous binary pass/fail system. To pass, the device must meet two criteria for both SBP and Diastolic Blood Pressure (DBP):
- Criterion 1 (Mean Error): The mean difference of the paired measurements between the test device and the reference standard must be ≤ 5.0 mmHg.
- Criterion 2 (Standard Deviation): The standard deviation of the mean subject differences must be ≤ 8.0 mmHg.
A sample size of 85 subjects is the minimum requirement for a general validation, with 35 subjects per sub-group for specific population claims (e.g., pediatric, pregnancy, elderly, renal disease).
Common Validation Pitfall: Failure to recruit the required number of subjects in the extreme blood pressure ranges (low <100 mmHg and high >160 mmHg) is a frequent reason for clinical study rejection by Notified Bodies and Regulatory Authorities.
Implementation Highlights for Clinical Trials
Executing a compliant clinical investigation under this standard requires meticulous logistical planning and strict adherence to protocol.
- Observer Training: Two trained observers must perform auscultation simultaneously using a dual-head stethoscope. They must be blinded to the test device reading and to each other’s reference readings